Member of the Board of Directors
Novartis AG

     
　　Born in 1941, Mr. Jetzer earned master degrees in law and in economics at the University of Neuch?tel (Switzerland) and became a licensed attorney. After more than 10 years as General Secretary of the Swiss Federation of Commerce and Industry (today: "economiesuisse") in Zurich, he joined Sandoz in 1980.
　　
　　In 1981, Mr. Jetzer became Member of the Group Executive Board of Sandoz AG, as Group Chief Financial Officer and, from 1990 on, as Head of Management Resources and International Coordination. In 1995, he moved to the USA and became Vice Chairman and Chief Executive Officer of Sandoz Corporation in New York (NY), and Chairman and Chief Executive Officer of Sandoz Pharmaceuticals Corporation in East Hanover, NJ (USA). Mr. Jetzer returned to Basel on January 1, 1996 to serve as President of the Group Executive Board of Sandoz until the merger of Ciba and Sandoz to form Novartis AG took place on December 20, 1996.
　　
　　Since January 1, 1997, Mr. Jetzer has been serving as Member of the Board of Directors of Novartis AG (parent).  Mr. Jetzer is also on the Board of Directors of Bank Clariden, Zurich, and the Supervisory Board of the Compagnie Financière Michelin, Granges-Paccot (FR), Switzerland, as well as the Board of the Swiss-Chinese Chamber of Commerce and of the Switzerland-Latin America Chamber of Commerce. Mr. Jetzer is a member of the Sponsoring Committee of the University of Zurich (Switzerland) and a member of the Supervisory Board of the Institute for Neurosciences of the University of Zurich. Besides, he is a member of the Supervisory Board of the Lucerne Festival Foundation, Lucerne (Switzerland).

Novartis AG

Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health. In 2006, the Groups businesses achieved sales of USD37.0 billion and a net income of USD7.2 billion. The Group invested approximately USD5.36 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ about 100,000 people and operate in over 140 countries around the world. According to the Business Weeks ranking in 2005 based on market capitalization, Novartis is the biggest company in Switzerland, the 20th in the world and the third in pharmaceuticals. Novartis is a leading innovative pharmaceutical and consumer health company in the world who has the most strong capability in R&D. Geigy, one predecessor of Novartis, began to sell dyestuff in China as early as 1886. The other 2 predecessors, Ciba and Sandoz, set up their offices in Shanghai in the first half of the 20th century. The real development came after 1979. Ciba-Geigy and Sandoz established several plants in China. Up to now, with a total investment of about USD330 million, Novartis has 6 enterprises and 1 research center in China covering the fields of pharmaceuticals, consumer health, eye-care, animal health and chemicals and intermediates for drugs, and employs about 2,500 people in mainland China. The total sales revenues of Novartis in China reached RMB2.12 billion in 2006

Editor: Yan